Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings GlaxoSmithKline Pharmaceuticals Limited: Strengths and Weaknesses

Highlights: GlaxoSmithKline Pharmaceuticals Limited
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Sales forecast by analysts have been recently revised upwards.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: GlaxoSmithKline Pharmaceuticals Limited
  • With an expected P/E ratio at 43.02 and 37.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
526.04Cr - - - -
1,03400Cr
A
67TCr -
BBB
- -
46TCr
AA
-
35TCr
AA
31TCr
AAA
26TCr
A
24TCr
A
21TCr
A
19TCr
AA
Average 37.22TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Ratings GlaxoSmithKline Pharmaceuticals Limited